Molecular moieties within newly discovered pathophysiological pathways in atherothrombosis represent potential biomedical risk markers for cardiovascular disease. Their discovery is important in that a large proportion of cardiovascular disease is unexplained by ‘conventional' risk markers, and that novel markers may pave the way to new targets for intervention. Many candidate markers have been identified, among which inflammatory and haemostatic factors are prominent. This review will examine the evidence for the roles of key novel risk markers in cardiovascular disease, against criteria which define causality as well as potential clinical utility.
KannelWB.Cardiovascular risk factors in the elderly. Coron Artery Dis1997; 8:565–575.
2.
KannelWBMcGeeDGordonT.A general cardiovascular risk profile: The Framingham Study. Am J Cardiol1976; 38:46–51.
3.
KoenigW.Inflammation and coronary heart disease: An overview. Cardiol Rev2001; 9:31–35.
4.
Bradford-HillA.The environment and disease: Association or causation? Proc Royal Soc Med1965; 58:295.
5.
BoringLGoslingJClearyMCharoIF.Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature1998; 394:894–897.
6.
GuLOkadaYClintonSKGerardCSukhovaGKLibbyPAbsence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell1998; 2:275–281.
7.
MachFSautyAIarossiASSukhovaGKNeoteKLibbyPDifferential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest1999; 104:1041–1050.
8.
RossR.The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature1993; 362:801–809.
9.
LibbyPRidkerPMMaseriA.Inflammation and atherosclerosis. Circulation2002; 105:1135–1143.
10.
AlexanderRW.Inflammation and coronary artery disease. N Engl J Med1994; 331:468–469.
11.
PepysMB.The acute phase response and C-reactive protein. In: WeatherallDJLedinghamJGGWarrellDA, editors: Oxford textbook of medicine. Vol. 2. Oxford: Oxford University Press; 1995, pp. 1527–1533.
12.
RidkerPMCushmanMStampferMJTracyRPHennekensCH.Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med1997; 336:973–979.
13.
RidkerPMCushmanMStampferMJTracyRPHennekensCH.Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation1998; 97:425–428.
14.
RidkerPMGlynnRJHennekensCH.C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation1998; 97:2007–2011.
15.
RidkerPMRifaiNClearfieldMDownsJRWeisSEMilesJSMeasurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med2001; 344:1959–1965.
16.
KullerLHTracyRPShatenJMeilahnEN.Relation of C-reactive protein and coronary heart disease in the MRFIT nested case—control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol1996; 144:537–547.
17.
TracyRP.Inflammation markers and coronary heart disease. Curr Opin Lipidol1999; 10:435–441.
18.
TracyRPLemaitreRNPsatyBMIvesDGEvansRWCushmanMRelationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol1997; 17:1121–1127.
19.
RidkerPMBuringJEShihJMatiasMHennekensCH.Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation1998; 98:731–733.
20.
KoenigWSundMFrohlichMFischerHGLowelHDoringAC-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation1999; 99:237–242.
21.
RoivainenMViik-KajanderMPalosuoTToivanenPLeinonenMSaikkuPInfections, inflammation, and the risk of coronary heart disease. Circulation2000; 101:252–257.
22.
RidkerPM.C-reactive protein and risks of future myocardial infarction and thrombotic stroke. Eur Heart J1998; 19:1–3.
23.
RidkerPMHennekensCHBuringJERifaiN.C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med2000; 342:836–843.
24.
LiuzzoGBiasucciLMGallimoreJRGrilloRLRebuzziAGPepysMBThe prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med1994; 331:417–424.
25.
BiasucciLMLiuzzoGBuffonAMaseriA.The variable role of inflammation in acute coronary syndromes and in restenosis. Semin Interv Cardiol1999; 4:105–110.
26.
de WinterRJBholasinghRLijmerJGKosterRWGorgelsJPSchoutenYIndependent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction. Cardiovasc Res1999; 42:240–245.
27.
SacksFMPfefferMAMoyeLARouleauJLRutherfordJDColeTGThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med1996; 335:1001–1009.
28.
RobeyFAOhuraKFutakiSFujiiNYajimaHGoldmanNProteolysis of human C-reactive protein produces peptides with potent immunomodulating activity. J Biol Chem1987; 262:7053–7057.
29.
HeuertzRMPiquetteCAWebsterRO.Rabbits with elevated serum C-reactive protein exhibit diminished neutrophil infiltration and vascular permeability in C5a-induced alveolitis. Am J Pathol1993; 142:319–328.
30.
TilgHVannierEVachinoGDinarelloCAMierJW.Anti-inflammatory properties of hepatic acute phase proteins: Preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J Exp Med1993; 178:1629–1636.
31.
ClelandSJSattarNPetrieJRForouhiNGElliottHLConnellJM.Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Colch)2000; 98:531–535.
32.
FichtlschererSRosenbergerGWalterDHBreuerSDimmelerSZeiherAM.Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation2000; 102:1000–1006.
33.
FichtlschererSZeiherAM.Endothelial dysfunction in acute coronary syndromes: Association with elevated C-reactive protein levels. Ann Med2000; 32:515–518.
34.
LagrandWKNiessenHWWolbinkGJJasparsLHVisserCAVerheugtFWC-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation1997; 95:97–103.
35.
FolsomARPankowJSTracyRPArnettDKPeacockJMHongYAssociation of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol2001; 88:112–117.
36.
YuHRifaiN.High-sensitivity C-reactive protein and atherosclerosis: From theory to therapy. Clin Biochem2000; 33:601–610.
37.
SnickV.Interleukin-6: An overview. Annu Rev Immunol1990; 8:253–278.
38.
BaumannHGauldieJ.Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med1990; 7:147–159.
39.
MestriesJCKruithofEKGasconMPHerodinFAgayDYthierA.In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons. Eur Cytokine Netw1994; 5:275–281.
40.
LoppnowHLibbyP.Comparative analysis of cytokine induction in human vascular endothelial and smooth muscle cells. Lymphokine Res1989; 8:293–299.
41.
LoppnowHLibbyP.Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1. Cell Immunol1989; 122:493–503.
42.
RusHGVlaicuRNiculescuF.Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis1996; 127:263–271.
43.
Mohamed-AliVGoodrickSRaweshAKatzDRMilesJMYudkinJSSubcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab1997; 82:4196–4200.
44.
HerityNA.Interleukin 6: A message from the heart. Heart2000; 84:9–10.
45.
HotamisligilGSMurrayDLChoyLNSpiegelmanBM.Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA1994; 91:4854–4858.
46.
HardardottirIMoserAHMemonRGrunfeldCFeingoldKR.Effects of TNF, IL-1, and the combination of both cytokines on cholesterol metabolism in Syrian hamsters. Lymphokine Cytokine Res1994; 13:161–166.
47.
van der PollTvan DeventerSJPasterkampGvan MourikJABullerHRten CateJW.Tumor necrosis factor induces von Willebrand factor release in healthy humans. Thromb Haemost1992; 67:623–626.
48.
YudkinJSKumariMHumphriesSEMohamed-AliV.Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis2000; 148:209–214.
49.
RidkerPMRifaiNStampferMJHennekensCH.Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation2000; 101:1767–1772.
50.
VolpatoSGuralnikJMFerrucciLBalfourJChavesPFriedLPCardiovascular disease, interleukin-6, and risk of mortality in older women: The women's health and aging study. Circulation2001; 103:947–953.
51.
HarrisTBFerrucciLTracyRPCortiMCWacholderSEttingerWHJr.Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med1999; 106:506–512.
52.
SmiejaMYusufSLonnEGnarpeJGnarpeHYiQInflammatory markers and risk of subsequent cardiovascular events in the HOPE trial [abstract]. J Am Heart Assoc2001; 104:3714A.
53.
PoberJSBevilacquaMPMendrickDLLapierreLAFiersWGimbroneMAJr.Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol1986; 136:1680–1687.
54.
FukumotoYShimokawaHItoAKadokamiTYonemitsuYAikawaMInflammatory cytokines cause coronary arteriosclerosis-like changes and alterations in the smooth-muscle phenotypes in pigs. J Cardiovasc Pharmacol1997; 29:222–231.
55.
DaviesMJGordonJLGearingAJPigottRWoolfNKatzDThe expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol1993; 171:223–229.
56.
LiHCybulskyMIGimbroneMAJr.LibbyP.Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am J Pathol1993; 143:1551–1559.
57.
CybulskyMIIiyamaKLiHZhuSChenMIiyamaMA major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest2001; 107:1255–1262.
58.
HaughtWHMansourMRothleinRKishimotoTKMainolfiEAHendricksJBAlterations in circulating intercellular adhesion molecule-1 and L-selectin: Further evidence for chronic inflammation in ischemic heart disease. Am Heart J1996; 132:1–8.
59.
MulvihillNTFoleyJBMurphyRCreanPWalshM.Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol2000; 36:1210–1216.
60.
RidkerPMHennekensCHRoitman-JohnsonBStampferMJAllenJ.Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet1998; 351:88–92.
61.
BlankenbergSRupprechtHJBickelCPeetzDHafnerGTiretLCirculating cell adhesion molecules and death in patients with coronary artery disease. Circulation2001; 104:1336–1342.
62.
McCullyKS.Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol1969; 56:111–128.
63.
FolsomARNietoFJMcGovernPGTsaiMYMalinowMREckfeldtJHProspective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study. Circulation1998; 98:204–210.
64.
BousheyCJBeresfordSAOmennGSMotulskyAG.A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA1995; 274:1049–1057.
65.
ChristenWGAjaniUAGlynnRJHennekensCH.Blood levels of homocysteine and increased risks of cardiovascular disease: Causal or casual? Arch Intern Med2000; 160:422–434.
66.
TsaiJCPerrellaMAYoshizumiMHsiehCMHaberESchlegelRPromotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA1994; 91:6369–6373.
67.
Ei-KhairyLUelandPMNygardORefsumHVollsetSE.Lifestyle and cardiovascular disease risk factors as determinants of total cysteine in plasma: The Hordaland Homocysteine Study. Am J Clin Nutr1999; 70:1016–1024.
68.
EikelboomJWLonnEGenestJJrHankeyGYusufS.Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med1999; 131:363–375.
69.
Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. BMJ1998; 316:894–898.
70.
FordESSmithSJStroupDFSteinbergKKMuellerPWThackerSB.Homocyst(e)ine and cardiovascular disease: A systematic review of the evidence with special emphasis on case—control studies and nested case—control studies. Int J Epidemiol2002; 31:59–70.
71.
ShipchandlerMTMooreEG.Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMx analyzer. Clin Chem1995; 41:991–994.
72.
ZighettiMLChantarangkulVTripodiAMannucciPMCattaneoM.Determination of total homocysteine in plasma: Comparison of the Abbott IMx immunoassay with high performance liquid chromatography. Haematologica2002; 87:89–94.
73.
MeadeTWMellowsSBrozovicMMillerGJChakrabartiRRNorthWRHaemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet1986; ii:533–537.
74.
ErnstEReschKL.Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med1993; 118:956–963.
LefkovitsJPlowEFTopolEJ.Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med1995; 332:1553–1559.
77.
EberBSchumacherM.Fibrinogen: Its role in the hemostatic regulation in atherosclerosis. Semin Thromb Hemost1993; 19:104–107.
78.
SmithEB.Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol1986; 15:355–370.
79.
KannelWBD'AgostinoRBBelangerAJ.Fibrinogen, cigarette smoking, and risk of cardiovascular disease: Insights from the Framingham Study. Am Heart J1987; 113:1006–1010.
80.
LeeAJLoweGDWoodwardMTunstall-PedoeH.Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: The Scottish Heart Health Study. Br Heart J1993; 69:338–342.
81.
TracyRPBovillEGYanezDPsatyBMFriedLPHeissGFibrinogen and Factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly: Results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol1995; 15:1269–1279.
82.
TracyRPArnoldAMEttingerWFriedLMeilahnESavageP.The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: Results from the cardiovascular health study. Arterioscler Thromb Vasc Biol1999; 19:1776–1783.
83.
MaJHennekensCHRidkerPMStampferMJ.A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. J Am Coll Cardiol1999; 33:1347–1352.
84.
SatoSNakamuraMIidaMNaitoYKitamuraAOkamuraTPlasma fibrinogen and coronary heart disease in urban Japanese. Am J Epidemiol2000; 152:420–423.
85.
FolsomARAleksicNAhnCBoerwinkleEWuKK.Beta-fibrinogen gene −455G/A polymorphism and coronary heart disease incidence: The Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol2001; 11:166–170.
86.
DaneshJCollinsRApplebyPPetoR.Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA1998; 279:1477–1482.
87.
MarescaGDi BlasioAMarchioliRDi MinnoG.Measuring plasma fibrinogen to predict stroke and myocardial infarction: An update. Arterioscler Thromb Vasc Biol1999; 19:1368–1377.
88.
SmithFBLeeAJFowkesFGPriceJFRumleyALoweGD.Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arteriosclerosis Thrombosis and Vascular Biology1997; 17:3321–3325.
89.
FolsomARRosamondWDShaharECooperLSAleksicNNietoFJProspective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation1999; 100:736–742.
90.
GenestJJrCohnJS.Clustering of cardiovascular risk factors: Targeting high-risk individuals. Am J Cardiol1995; 76:8–20.
91.
MuldoonMFHerbertTBPattersonSMKamenevaMRaibleRManuckSB.Effects of acute psychological stress on serum lipid levels, hemoconcentration, and blood viscosity. Arch Intern Med1995; 155:615–620.
92.
IacovielloL.Genes encoding fibrinogen and cardiovascular risk. Hypertension2001; 38:1199–1203.
93.
SweetnamPMYarnellJWLoweGDBakerIAO'BrienJRRumleyAThe relative power of heat-precipitation nephelometric and clottable (Clauss) fibrinogen in the prediction of ischaemic heart disease: The Caerphilly and Speedwell studies. Br J Haematol1998; 100:582–588.
94.
Di MinnoGManciniM.Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arteriosclerosis1990; 10:1–7.
RuggeriZM.Von Willebrand factor as a target for antithrombotic intervention. Circulation1992; 86:III26–29.
97.
MeadeTWCooperJAStirlingYHowarthDJRuddockVMillerGJ.Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol1994; 88:601–607.
98.
FolsomAR.Hemostatic risk factors for atherothrombotic disease: An epidemiologic view. Thromb Haemost2001; 86:366–373.
99.
RumleyALoweGDSweetnamPMYarnellJWFordRP.Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol1999; 105:110–116.
100.
JanssonJHNilssonTKJohnsonO.Von Willebrand factor in plasma: A novel risk factor for recurrent myocardial infarction and death. Br Heart J1991; 66:351–355.
101.
ThogersenAMJanssonJHBomanKNilssonTKWeinehallLHuhtasaariFHigh plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation1998; 98:2241–2247.
102.
MurdockPJWoodhamsBJMatthewsKBPasiKJGoodallAH.Von Willebrand factor activity detected in a monoclonal antibody-based ELISA: An alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost1997; 78:1272–1277.
103.
TateyamaHHinoJMinaminoNKangawaKOgiharaTMatsuoH.Characterization of immunoreactive brain natriuretic peptide in human cardiac atrium. Biochem Biophys Res Commun1990; 166:1080–1087.
104.
MacGregorASPriceJFHauCMLeeAJCarsonMNFowkesFGR.Role of systolic blood pressure and plasma triglycerides in diabetic peripheral arterial disease: The Edinburgh Artery Study. Diabetes Care1999; 22:453–458.
105.
HuntPJRichardsAMNichollsMGYandleTGDoughtyRNEspinerEA.Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment. Clin Endocrinol (Oxf)1997; 47:287–296.
106.
CowieMRMendezGF.BNP and congestive heart failure. Prog Cardiovasc Dis2002; 44:293–321.
107.
McDonaghTARobbSDMurdochDRMortonJJFordIMorrisonCEBiochemical detection of left-ventricular systolic dysfunction. Lancet1998; 351:9–13.
108.
DriesDLStevensonLW.Brain natriuretic peptide as bridge to therapy for heart failure. Lancet2000; 355:1112–1113.
109.
McDonaghTACunninghamADMorrisonCEMcMurrayJJFordIMortonJJLeft ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart2001; 86:21–26.
110.
RichardsAMNichollsMGYandleTGFramptonCEspinerEATurnerJGPlasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation1998; 97:1921–1929.
111.
RichardsAMNichollsMGYandleTGIkramHEspinerEATurnerJGNeuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. Heart1999; 81:114–120.
112.
de LemosJAMorrowDABentleyJHOmlandTSabatineMSMcCabeCHThe prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med2001; 345:1014–1021.
113.
SabatineMSMorrowDAde LemosJAGibsonCMMurphySARifaiNMultimarker approach to risk stratification in non-ST elevation acute coronary syndromes: Simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation2002; 105:1760–1763.
114.
WallenTLandahlSHednerTNakaoKSaitoY.Brain natriuretic peptide predicts mortality in the elderly. Heart1997; 77:264–267.
115.
TroughtonRWFramptonCMYandleTGEspinerEANichollsMGRichardsAM.Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet2000; 355:1126–1130.
116.
CowieMR.BNP: Soon to become a routine measure in the care of patients with heart failure? Heart2000; 83:617–618.
117.
JagerAvan HinsberghVWKostensePJEmeisJJYudkinJSNijpelsGVon Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: The Hoorn Study. Arterioscler Thromb Vasc Biol1999; 19:3071–3078.
118.
GusseklooJSchaapMCFrolichMBlauwGJWestendorpRG.C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol2000; 20:1047–1051.
119.
MendallMAStrachanDPButlandBKBallamLMorrisJSweetnamPMC-reactive protein: Relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J2000; 21:1584–1590.
120.
RostNSWolfPAKaseCSKelly-HayesMSilbershatzHMassaroJMPlasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: The Framingham study. Stroke2001; 32:2575–2579.
121.
KervinenHPalosuoTManninenVTenkanenLVaaralaOManttariM.Joint effects of C-reactive protein and other risk factors on acute coronary events. Am Heart J2001; 141:580–585.
122.
StampferMJMalinowMRWillettWCNewcomerLMUpsonBUllmannDA prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA1992; 268:877–881.
123.
HopkinsPNWuLLWuJHuntSCJamesBCVincentGMHigher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol1995; 15:1314–1320.
124.
RobinsonKMayerELMillerDPGreenRvan LenteFGuptaAHyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation1995; 92:2825–2830.
125.
ArnesenERefsumHBonaaKHUelandPMFordeOHNordrehaugJE.Serum total homocysteine and coronary heart disease. Int J Epidemiol1995; 24:704–709.
126.
PerryIJRefsumHMorrisRWEbrahimSBUelandPMShaperAG.Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet1995; 346:1395–1398.
127.
MalinowMRDucimetierePLucGEvansAEArveilerDCambienFPlasma homocyst(e)ine levels and graded risk for myocardial infarction: Findings in two populations at contrasting risk for coronary heart disease. Atherosclerosis1996; 126:27–34.
128.
GrahamIMDalyLERefsumHMRobinsonKBrattstromLEUelandPMPlasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA1997; 277:1775–1781.
129.
EvansRWShatenBJHempelJDCutlerJAKullerLH.Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol1997; 17:1947–1953.
130.
NygardONordrehaugJERefsumHUelandPMFarstadMVollsetSE.Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med1997; 337:230–236.
131.
WhincupPHRefsumHPerryIJMorrisRWalkerMLennonLSerum total homocysteine and coronary heart disease: Prospective study in middle aged men. Heart1999; 82:448–454.
132.
VerhoefPHennekensCHAllenRHStablerSPWillettWCStampferMJ.Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol1997; 79:799–801.
133.
StehouwerCDWeijenbergMPvan den BergMJakobsCFeskensEJKromhoutD.Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: A 10-year follow-up. Arterioscler Thromb Vasc Biol1998; 18:1895–1901.
134.
WaldNJWattHCLawMRWeirDGMcPartlinJScottJM.Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention. Arch Int Med1998; 158:862–867.
135.
RidkerPMMansonJEBuringJEShihJMatiasMHennekensCH.Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA1999; 281:1817–1821.
136.
FallonUBBen-ShlomoYElwoodPUbbinkJBSmithGD.Homocysteine and coronary heart disease in the Caerphilly cohort: A 10 year follow up. Heart2001; 85:153–158.
137.
CremerPNagelDLabrotBMannHMucheRElsterHLipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: Results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest1994; 24:444–453.
138.
HeinrichJBalleisenLSchulteHAssmannGvan de LooJ.Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb1994; 14:54–59.
139.
FolsomARSzkloMStevensJLiaoFSmithREckfeldtJH.A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care1997; 20:935–942.
140.
WoodwardMLoweGDRumleyATunstall-PedoeH.Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study. Eur Heart J1998; 19:55–62.
141.
CooperJAMillerGJBauerKAMorrisseyJHMeadeTWHowarthDJComparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation2000; 102:2816–2822.
142.
SaitoIFolsomARBrancatiFLDuncanBBChamblessLEMcGovernPG.Non-traditional risk factors for coronary heart disease incidence among persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med2000; 133:81–91.
